Cargando…

Effects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in rats

OBJECTIVE: To determine the effects of exogenous glucagon-like peptide-2 (GLP-2), with or without massive distal bowel resection, on adaptation of jejunal mucosa, enteric neurons, gut hormones and tissue reserves in rats. BACKGROUND: GLP-2 is a gut hormone known to be trophic for small bowel mucosa,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Sarah W., de Heuvel, Elaine, Wallace, Laurie E., Hartmann, Bolette, Holst, Jens J., Brindle, Mary E., Chelikani, Prasanth K., Sigalet, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524396/ https://www.ncbi.nlm.nih.gov/pubmed/28738080 http://dx.doi.org/10.1371/journal.pone.0181453

Ejemplares similares

Intestinal Growth in Glucagon Receptor Knockout Mice Is Not Associated With the Formation of AOM/DSS-Induced Tumors
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice
por: Hytting-Andreasen, Rasmus, et al.
Publicado: (2018)

The Effect of Glucagon-Like Peptide-2 Receptor Agonists on Colonic Anastomotic Wound Healing
por: Redstone, Heather A., et al.
Publicado: (2010)

Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays
por: Boer, Geke Aline, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
por: Asmar, Ali, et al.
Publicado: (2017)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Segmental reversal of the distal small intestine in a short bowel syndrome model in piglets showed detrimental effect on weight gain
por: Schmidt, Lasse Hartmann, et al.
Publicado: (2022)

Dietary Fiber Is Essential to Maintain Intestinal Size, L-Cell Secretion, and Intestinal Integrity in Mice
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Acute effects of glucagon‐like peptide‐1, GLP‐1(9–36 amide), and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers
por: Bremholm, Lasse, et al.
Publicado: (2017)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

Acute administration of interleukin‐6 does not increase secretion of glucagon‐like peptide‐1 in mice
por: Christiansen, Charlotte B., et al.
Publicado: (2018)

Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell Transplantation
por: Ebbesen, Maria, et al.
Publicado: (2021)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Peptone‐mediated glucagon‐like peptide‐1 secretion depends on intestinal absorption and activation of basolaterally located Calcium‐Sensing Receptors
por: Modvig, Ida M., et al.
Publicado: (2019)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study
por: Hansen, Nina L., et al.
Publicado: (2020)

Prolonged lipopolysaccharide‐induced illness elevates glucagon‐like peptide‐1 and suppresses peptide YY: A human‐randomized cross‐over trial
por: Brodersen, Katrine, et al.
Publicado: (2022)

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
por: Holst, Jens Juul
Publicado: (2022)

Methods and Guidelines for Measurement of Glucagon in Plasma
por: Holst, Jens J., et al.
Publicado: (2019)

Differential circulating concentrations of adipokines, glucagon and adropin in a clinical population of lean, overweight and diabetic cats
por: Zapata, Rizaldy C., et al.
Publicado: (2017)

Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine
por: Modvig, Ida M., et al.
Publicado: (2020)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

Does PYY mediate resolution of diabetes following bariatric surgery?
por: Chelikani, Prasanth K.
Publicado: (2019)

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
por: Ørgaard, Anne, et al.
Publicado: (2017)

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study
por: Naimi, Rahim Mohammad, et al.
Publicado: (2021)

Postprandial Insulin Secretion After Gastric Bypass Surgery: The Role of Glucagon-Like Peptide 1
por: Holst, Jens Juul
Publicado: (2011)

Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass – a 2‐year follow‐up
por: Borghede, Märta, et al.
Publicado: (2018)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Low Protein Diets and Energy Balance: Mechanisms of Action on Energy Intake and Expenditure
por: Pezeshki, Adel, et al.
Publicado: (2021)

The anorexic hormone Peptide YY(3–36) is rapidly metabolized to inactive Peptide YY(3–34) in vivo
por: Toräng, Signe, et al.
Publicado: (2015)

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function
por: Jeppesen, P. B., et al.
Publicado: (2009)

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure
por: Pizzoferrato, Marco, et al.
Publicado: (2022)

Insulin and Glucagon: Partners for Life
por: Holst, Jens Juul, et al.
Publicado: (2017)

Case of Gunshot-Wound of Intestines Resection of Bowels—Death
por: Cupples, Geo.
Publicado: (1887)

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males
por: Skov, Jeppe, et al.
Publicado: (2014)

Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice
por: Galsgaard, Katrine D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_si8tr6c4e1hjnuoiudqvc26i89